Sentences with phrase «organoid technology»
Hugo de Jonge, an associate professor at Erasmus Medical Center in The Netherlands and director of the MDI Biological Laboratory's new biomedical innovation course, «Applications of Organoid Technology,» discusses the potential of this fascinating new «mini-organ» technology in this exclusive editorial in Regenerative Medicine Network.
https://mdibl.org/
The MDI Biological Laboratory has announced that it will offer a one - week intensive course May 27 through June 2, 2018, entitled «Applications of Organoid Technology» in partnership with Hubrecht Organoid Technology (The HUB), a non-profit organization based in Utrecht, Netherlands.
«Our organoid course is one of only a handful in the United States to offer an intensive experience in organoid technology.
The team used pancreatic organoid technology developed in the lab of Professor David Tuveson, Director of CSHL's Cancer Center and Director of Research for the Lustgarten Foundation.
The directors of the organoid course are Hugo de Jonge, Ph.D, professor at Erasmus University Medical Center (Erasmus MC) in Rotterdam, Netherlands, and a visiting professor at the MDI Biological Laboratory, and Robert Vries, Ph.D., managing director at Foundation Hubrecht Organoid Technology.
BAR HARBOR, MAINE — The MDI Biological Laboratory in Bar Harbor, Maine, has announced that it will offer a one - week intensive course May 27 through June 2, 2018 entitled «Applications of Organoid Technology» in partnership with Hubrecht Organoid Technology (The HUB), a non-profit organization based in Utrecht, Netherlands.
The organoid technology field has advanced enormously as a result of two key discoveries.
Due to the high efficiency of establishing organoid models from different tissues and diseases, such as cancer, organoid technology allows the generation of large living biobanks of tumor organoids that are amenable for middle - throughput drug screens and may allow personalized therapy design, as a complement to cell line and xenograft - based drug studies (7,19).
However, despite its marked promise for disease modeling, development of novel therapies, and regenerative medicine, stem cell derived organoid technology faces many remaining challenges.
«The use of a mouse tumor - derived matrix would limit any future applications of these organoid technologies in humans, and this work opens the door to research directed specifically for clinical applications,» noted Asma Nusrat, study co-author and the Aldred Scott Warthin Professor and Director of Experimental Pathology in the University of Michigan's School of Medicine.
Not exact matches
«It is highly likely that organoids will revolutionize therapy of many severe diseases,» says Rudolf Jaenisch, a stem cell scientist at the Massachusetts Institute of Technology in Cambridge.
Stem cell technology has advanced so much that scientists can grow miniature versions of human brains — called organoids, or mini-brains if you want to be cute about it — in the lab, but medical ethicists are concerned about recent developments in this field involving the growth of these tiny brains in other animals.
Single - cell technologies will be applied to experimental model systems such as organoids, miniature organs grown in the petri dish from one or more cells.
ANN ARBOR, Mich — By combining engineered polymeric materials known as hydrogels with complex intestinal tissue known as organoids — made from human pluripotent stem cells — researchers have taken an important step toward creating a new technology for controlling the growth of these organoids and using them for treating wounds in the gut that can be caused by disorders such as inflammatory bowel disease (IBD).
The experts explain that many of the state - of - the - art technologies are required to tease out relevant information from model systems, whether these be organoids or «classical animal models such as the fruit fly, zebra fish or mouse,» adds Milán.
Researchers had developed the technologies needed to create organoids years before — how to grow cells in culture, how to isolate stem cells from human tissue, and how to coax the stem cells, undifferentiated and immature, to become specific types of cells at later stages of development.
Researchers from Brigham and Women's Hospital are leveraging these new technologies to study the effects of DISC1 mutations in cerebral organoids - «mini brains» - cultured from human stem cells.
The team is utilizing SU2C's unique «tumor organoid» technology in which an individual patient's tumor cells are grown in the laboratory, creating «mini tumors» which can then be tested to see if a particular treatment is optimal.
The new platform combines microfluidic lab - on - a-chip technology with physiologically relevant spheroids to enable formation and long - term culture of 3D multicellular tumours / organoids for drug screening / profiling and individualized chemosensitivity testing.
Furthermore, organoids were subjected to in vitro differentiation and genome editing using CRISPR / Cas9 technology.
Within the scope of personalized medicine, this technology presents immense possibilities for testing patient - derived multicellular tumour spheroids / organoids (comprising cancer cells, stromal cells, cancer stem cells and / or immune cells) for disease / biomarker - oriented drug activity and profiling using single - and pair-wise standard / targeted drug combinations.